Home Biotech Stocks Page 136

Biotech Stocks

Latest

Insys Therapeutics Presents Study Results Showing Rapid Absorption Of Epinephrine

ME Staff - February 26, 2019

Veritas Pharma Doses First Subject In Clinical Study Of CTL-X

OWC Pharmaceutical Cannabis Ointment Set To Proceed To PII After Positive PI Data

Reliq Health Technologies Expands Leadership Team As Investigations Continue

Zynerba Gives Clinical Update, Lifelong Impact Of ZYN002

Amgen, Inc. (NASDAQ:AMGN)’s Enbrel To Face Competition From Biogen Inc (NASDAQ:BIIB)’s...

Andy Parker - January 18, 2016 0

BioMarin, Sarepta’s Loss Could Be PTC’s Gain

Roger Hannington - January 18, 2016 0

Vertex Eyes a Half Billion Dollar Boost with Upcoming sNDA Decision

Jennifer Aldershot - January 15, 2016 0

Thursday’s Movers and Shakers in Biotech

Jennifer Aldershot - January 14, 2016 0

Abeona Therapeutics Secures Key Regulatory Approvals for Clinical Trials In Europe

- January 14, 2016 0

enGene Shines with a Host of Big Name Collaborations

- January 13, 2016 0

Here’s how to get an Exposure to Moderna’s Private Pipeline

Roger Hannington - January 12, 2016 0

Ariad is Targeting a Japanese Payday with Iclusig

- January 11, 2016 0

Is Guardant Next in Line for a Big Pharma Suitor?

Jennifer Aldershot - January 8, 2016 0

Amgen is Targeting a Blockbuster SOC Upheaval in Multiple Myeloma

ME Staff - January 7, 2016 0

1...135136137...146 Page 136 of 146

EDITOR PICKS

Weekly Roundup on the Cannabis Sector & Psychedelic Sector 11-11-2024

November 10, 2024

Weekly Roundup on the Cannabis Sector & Psychedelic Sector 10-28-2024

October 27, 2024

Weekly Roundup on the Cannabis Sector & Psychedelic Sector 10-14-24

October 13, 2024

Weekly Biotech Report covering – Opko Health Inc (NYSE:OPK) Intercept...

April 11, 2016

Facebook Inc – (NASDAQ:FB) Might Be Moving Away From Its...

April 8, 2016

Biotechnology Movers: Here’s Why Citius Pharmaceuticals Inc (NASDAQ:CTXR) Is Running Right...

November 8, 2017

ABOUT US

Market Exclusive offers the latest financial news and analysis for selected US stocks and securities. We are an investor driven research platform where new investment ideas from a exclusively selected group of seasoned investment analysts and qualified members from various disciplines are able to deliver their investment thesis’ across various industries and sectors. Our burgeoning team is comprised of individuals with strong backgrounds from various disciplines and businesses. Our goal is to provide an exclusive forum for contributors and users to leverage the knowledge base in order to make smarter investing decisions. At Market Exclusive, we believe that quality information from experienced well seasoned contributors provide our members with an edge that allows them to make wise investment choices. Market Exclusive is not a registered investment broker/dealer. The content on this site is for informational purposes only. Additionally, the content on this site does not represent the views of Market Exclusive and is solely a representation of the authors who publish them. Before investing in any security you should do your own due diligence and consult with a registered broker or financial advisor.